Detalles de la búsqueda
1.
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial.
Diabetes Obes Metab
; 26(2): 503-511, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37860918
2.
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922.
Diabetes Obes Metab
; 24 Suppl 1: 27-42, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34708913
3.
C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.
Diabetes Obes Metab
; 24(10): 1912-1926, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35676794
4.
Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.
Diabetes Obes Metab
; 23(1): 166-174, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33001554
5.
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
Diabetes Obes Metab
; 23(7): 1588-1593, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33687748
6.
Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study.
Diabetes Metab Res Rev
; 36(6): e3304, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32118347
7.
The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.
Diabetes Obes Metab
; 22(5): 743-754, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31930670
8.
Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials.
Diabetes Obes Metab
; 22(10): 1880-1885, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32515543
9.
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
Diabetes Obes Metab
; 22(9): 1664-1669, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32314521
10.
Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
Diabetes Obes Metab
; 22(3): 315-323, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31608548
11.
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
Diabetes Obes Metab
; 22(8): 1369-1377, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32243043
12.
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.
Diabetes Obes Metab
; 21(2): 402-407, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30160030
13.
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.
Diabetes Obes Metab
; 21(2): 321-329, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30520217
14.
Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology.
Curr Diab Rep
; 18(10): 83, 2018 08 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30121746
15.
Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus.
Diabetes Obes Metab
; 20(12): 2894-2898, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29943493
16.
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
Diabetes Obes Metab
; 20(1): 121-128, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28661585
17.
Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
Diabetes Obes Metab
; 20(11): 2541-2550, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29888454
18.
Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Diabetes Obes Metab
; 19(11): 1546-1554, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449412
19.
A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short-term study.
Diabetes Obes Metab
; 24(12): 2474-2477, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35971275
20.
Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis.
Diabetes Obes Metab
; 24(2): 327-331, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34595824